Previous close | 66.29 |
Open | 65.87 |
Bid | 65.80 x 1200 |
Ask | 66.26 x 1100 |
Day's range | 65.72 - 66.29 |
52-week range | 53.63 - 71.70 |
Volume | |
Avg. volume | 6,477,188 |
Market cap | 204.626B |
Beta (5Y monthly) | 0.12 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.45 (2.19%) |
Ex-dividend date | 11 Aug 2022 |
1y target est | N/A |
Whether it's thanks to a winning business model or timely good news, some companies are taking the bear market in stride, and some are even crushing it. Compared to the broader market's slump of around 5% in the last 12 months, AstraZeneca's (NASDAQ: AZN) stock has climbed 19%, making it a robust outperformer, to say the least. The company's success during the bear market is simply a matter of the strength of its drug development pipeline; with 184 projects in clinical trials and late-preclinical testing, it's among the largest in the world.
The board of AstraZeneca PLC ( LON:AZN ) has announced that it will be paying its dividend of $0.764 on the 12th of...
Moderna's (MRNA) earnings and sales beat expectations. The company also announces another $3-billion buyback program. Stock gains in pre-market.